ODN/Pam2

N/A

Report date: 2026/03/23 20:03:44
NMEFirst In Class

Base Information

Drug NameODN/Pam2
Drug Alias NamePUL-042ODN-M362/Pam2CSK4Pam2/ODNPam2CSK4/ODN-M362
ClassificationSmall molecules
Mechanisms of ActionToll like receptor 6 agonistsToll like receptor 9 agonistsToll like receptor 2 agonists
TargetsToll like receptor 6Toll like receptor 9Toll like receptor 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Pulmonary Disease, Chronic ObstructiveHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsYes
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer CenterTexas A&M University
China Registration ClassN/A

Develop Information

Active CompaniesPulmotect Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Hematologic Neoplasms
Inactive IndicationsPulmonary Disease, Chronic Obstructive

Other Information

ATC CodeN/A
Related LinksN/A